Loading
If daraxonrasib shrinks metastatic tumours this well, use it before surgery to make more locally advanced tumours operable.
The proposal is to give the RAS(ON) inhibitor daraxonrasib, with or without chemotherapy, before surgery for borderline resectable and locally advanced pancreatic ductal adenocarcinoma, to see whether it raises the R0 resection rate compared with mFOLFIRINOX. Surgery remains the only route to cure, yet only a minority of patients present with resectable disease. The rationale is the deep and rapid responses seen with daraxonrasib and zoldonrasib, oral dosing, ctDNA clearance as an early surrogate, and the fact that RASolute 303 and 304 already move the drug earlier. The test would be a randomised phase 2 with R0 resection as the primary endpoint. At an early clinical stage, it addresses the bottleneck of the undruggable drivers.
This is the paper Europe PMC returns for registry id NCT05379985 with the most citations, so it is the natural first reading for anyone following the trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.
One of the most cited trial reports Europe PMC returns for Daraxonrasib in Pancreatic ductal adenocarcinoma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One of the most cited reviews Europe PMC returns for Daraxonrasib in Pancreatic ductal adenocarcinoma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
Shares Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer, RASolute 302, RAS inhibitor combinations and sequence: pan-RAS plus G12D-selective, plus chemotherapy, and what to give after progression, Daraxonrasib.
Shares RASolute 302, RAS inhibitor combinations and sequence: pan-RAS plus G12D-selective, plus chemotherapy, and what to give after progression, Daraxonrasib, Borderline resectable pancreatic ductal adenocarcinoma.
Shares Zoldonrasib, RAS inhibitor combinations and sequence: pan-RAS plus G12D-selective, plus chemotherapy, and what to give after progression, Daraxonrasib, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question.
Shares Zoldonrasib, RAS inhibitor combinations and sequence: pan-RAS plus G12D-selective, plus chemotherapy, and what to give after progression, Daraxonrasib, KRAS & RAS inhibitors.
Shares Chemotherapy before surgery for every resectable pancreatic cancer, settled by the two perioperative trials rather than assumed, FOLFIRINOX / mFOLFIRINOX, Borderline resectable pancreatic ductal adenocarcinoma, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question.
Shares Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer, Daraxonrasib, KRAS & RAS inhibitors, Pancreatic ductal adenocarcinoma.
Shares Zoldonrasib, RASolute 302, RAS inhibitor combinations and sequence: pan-RAS plus G12D-selective, plus chemotherapy, and what to give after progression, Daraxonrasib.
Shares Chemotherapy before surgery for every resectable pancreatic cancer, settled by the two perioperative trials rather than assumed, FOLFIRINOX / mFOLFIRINOX, Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question.